ARTICLE | Clinical News
Ampio starts pivotal trial of Ampion for OA of the knee
May 17, 2017 9:01 PM UTC
Ampio Pharmaceuticals Inc. (NYSE-M:AMPE) began a blinded, placebo-controlled, pivotal trial evaluating single intra-articular injections of Ampion to treat Kellgren-Lawrence (KL) grade IV osteoarthritis (OA) of the knee.
Under FDA guidance, the 12-week trial will evaluate response rate as defined by Osteoarthritis Research Society International (OARSI) score in about 171 patients. Ampio said only the Ampion-treated group will be evaluated. The company said it will "advance necessary BLA activities" concurrently with the trial...
BCIQ Company Profiles